Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation

Aine McKillop, Nicola Duffy, John Lindsay, Brian Green, Steven Patterson, Finbarr O'Harte, Patrick Bell, Peter Flatt

Research output: Contribution to journalArticle

Abstract

Nateglinide restores early-phase insulin secretion to feeding and reduces postprandial hyperglycaemia in type 2 diabetes. This study evaluated the effects of nateglinide on dipeptidyl peptidase-IV (DPP-IV) activity and glucose-dependent insulinotropic polypeptide (GIP) degradation. Research design and methods Blood samples were collected from type 2 diabetic subjects (n=10, fasting glucose 9.36+/-1.2 mmol/l) following administration of oral nateglinide (120 mg) 10 min prior to a 75 g oral glucose load in a randomised crossover design.
Original languageEnglish
Pages (from-to)877-885
Number of pages9
JournalEuropean Journal of Endocrinology
Volume161
Issue number6
DOIs
Publication statusPublished - Dec 2009

Fingerprint

nateglinide
Dipeptidyl Peptidase 4
Glucose
Peptides
Hyperglycemia
Cross-Over Studies
Type 2 Diabetes Mellitus
Oral Administration
Fasting
Research Design
Insulin

Keywords

  • diabetes
  • insulin secretion
  • nateglinide
  • postprandial hyperglycaemia

Cite this

McKillop, Aine ; Duffy, Nicola ; Lindsay, John ; Green, Brian ; Patterson, Steven ; O'Harte, Finbarr ; Bell, Patrick ; Flatt, Peter . / Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation. In: European Journal of Endocrinology. 2009 ; Vol. 161, No. 6. pp. 877-885.
@article{6f7a45a9392042f7aab30476275f8c74,
title = "Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation",
abstract = "Nateglinide restores early-phase insulin secretion to feeding and reduces postprandial hyperglycaemia in type 2 diabetes. This study evaluated the effects of nateglinide on dipeptidyl peptidase-IV (DPP-IV) activity and glucose-dependent insulinotropic polypeptide (GIP) degradation. Research design and methods Blood samples were collected from type 2 diabetic subjects (n=10, fasting glucose 9.36+/-1.2 mmol/l) following administration of oral nateglinide (120 mg) 10 min prior to a 75 g oral glucose load in a randomised crossover design.",
keywords = "diabetes, insulin secretion, nateglinide, postprandial hyperglycaemia",
author = "Aine McKillop and Nicola Duffy and John Lindsay and Brian Green and Steven Patterson and Finbarr O'Harte and Patrick Bell and Peter Flatt",
year = "2009",
month = "12",
doi = "10.1530/EJE-09-0547",
language = "English",
volume = "161",
pages = "877--885",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica",
number = "6",

}

Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation. / McKillop, Aine; Duffy, Nicola; Lindsay, John; Green, Brian; Patterson, Steven; O'Harte, Finbarr; Bell, Patrick ; Flatt, Peter .

In: European Journal of Endocrinology, Vol. 161, No. 6, 12.2009, p. 877-885.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation

AU - McKillop, Aine

AU - Duffy, Nicola

AU - Lindsay, John

AU - Green, Brian

AU - Patterson, Steven

AU - O'Harte, Finbarr

AU - Bell, Patrick

AU - Flatt, Peter

PY - 2009/12

Y1 - 2009/12

N2 - Nateglinide restores early-phase insulin secretion to feeding and reduces postprandial hyperglycaemia in type 2 diabetes. This study evaluated the effects of nateglinide on dipeptidyl peptidase-IV (DPP-IV) activity and glucose-dependent insulinotropic polypeptide (GIP) degradation. Research design and methods Blood samples were collected from type 2 diabetic subjects (n=10, fasting glucose 9.36+/-1.2 mmol/l) following administration of oral nateglinide (120 mg) 10 min prior to a 75 g oral glucose load in a randomised crossover design.

AB - Nateglinide restores early-phase insulin secretion to feeding and reduces postprandial hyperglycaemia in type 2 diabetes. This study evaluated the effects of nateglinide on dipeptidyl peptidase-IV (DPP-IV) activity and glucose-dependent insulinotropic polypeptide (GIP) degradation. Research design and methods Blood samples were collected from type 2 diabetic subjects (n=10, fasting glucose 9.36+/-1.2 mmol/l) following administration of oral nateglinide (120 mg) 10 min prior to a 75 g oral glucose load in a randomised crossover design.

KW - diabetes

KW - insulin secretion

KW - nateglinide

KW - postprandial hyperglycaemia

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-72949089282&partnerID=8YFLogxK

U2 - 10.1530/EJE-09-0547

DO - 10.1530/EJE-09-0547

M3 - Article

AN - SCOPUS:72949089282

VL - 161

SP - 877

EP - 885

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 6

ER -